Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
about
Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
description
im Januar 2018 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2018
@uk
name
Short-course therapy for diarr ...... and tolerability of rifaximin
@en
Short-course therapy for diarr ...... and tolerability of rifaximin
@nl
type
label
Short-course therapy for diarr ...... and tolerability of rifaximin
@en
Short-course therapy for diarr ...... and tolerability of rifaximin
@nl
prefLabel
Short-course therapy for diarr ...... and tolerability of rifaximin
@en
Short-course therapy for diarr ...... and tolerability of rifaximin
@nl
P2860
P356
P1476
Short-course therapy for diarr ...... and tolerability of rifaximin
@en
P2093
Christopher Chang
P2860
P304
P356
10.2147/CEG.S167031
P407
P577
2018-01-01T00:00:00Z